Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming.
Saved in:
| Title: | Low-dose radiotherapy synergizes with PD-1 blockade to achieve durable survival in advanced NSCLC through antitumor neutrophil programming. |
|---|---|
| Authors: | Zhou L; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; Health Management Center, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, China., Liu Y; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China., Xing Z; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China., Wu Y; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China., Yang X; Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China., Chen S; Department of Laboratory Medicine, Clinical Laboratory Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China., Kang K; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, China., Wang M; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China., Zhou Z; Geneplus-Beijing Institute, Beijing, China., Huang M; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China., Gong Y; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China., Zhou L; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China., Zhou X; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China., Li J; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China., Yao Z; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, China., Zheng Q; Department of Laboratory Medicine, Clinical Laboratory Medicine Research Center, West China Hospital, Sichuan University, Chengdu, China., Kong FS; Department of Clinical Oncology, University of Hong Kong, Hong Kong, China., Niedermann G; Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; German Cancer Consortium (DKTK), Partner Site Freiburg; and German Cancer Research Center (DKFZ), Heidelberg, Germany., Luo R; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. luorenbu@gmail.com.; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, China. luorenbu@gmail.com., Lu Y; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. radyoulu@hotmail.com.; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, China. radyoulu@hotmail.com., Xue J; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. jianxin-xue@wchscu.edu.cn.; Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, China. jianxin-xue@wchscu.edu.cn. |
| Source: | Signal transduction and targeted therapy [Signal Transduct Target Ther] 2026 May 07; Vol. 11 (1). Date of Electronic Publication: 2026 May 07. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101676423 Publication Model: Electronic Cited Medium: Internet ISSN: 2059-3635 (Electronic) Linking ISSN: 20593635 NLM ISO Abbreviation: Signal Transduct Target Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2059-3635 |
|---|---|
| DOI: | 10.1038/s41392-026-02712-6 |
